On 20 January 2010 in the annual \u201cBaltic Market Awards\u201d ceremony of the Stock Exchange \u201cNasdaq OMX Riga\u201d Grindeks was awarded for the Best Investor Relations Online in the Baltic countries and became also the best company in terms of the Best Investor Relations in \u201cNasdaq OMX Riga\u201d in 2010.<\/p>\n\n\n\n
The members of the Evaluation Committee \u201cBaltic Market Awards\u201d represent academics, investors, finance analysts, media representatives and representatives of the Baltic stock exchanges. The Evaluation Committee is chaired by Geoffrey Mazullo, corporate Governance expert and principal of Emerging Markets ESG. The company analysis was conducted by students from the Stockholm School of Economics in Riga, under the supervision of the evaluation committee and the Nasdaq OMX Baltic stock exchanges.<\/p>\n\n\n\n
Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Product portfolio of Grindeks consists of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.<\/p>\n\n\n\n
Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. JSC Grindeks shares are listed in the Official List of \u201cNasdaq OMX Riga\u201d.<\/p>\n\n\n\n